BURU
Nuburu, Inc.
Industrial - Machinery
Market Cap$1M
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BURU vs LYRA
Revenue, margins, valuation, and 5-year total return — side by side.
LYRA
Lyra Therapeutics, Inc.
Biotechnology
Market Cap$781K
5Y Perf.-99.8%
BURU vs LYRA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BURU | LYRA |
|---|---|---|
| Industry | Industrial - Machinery | Biotechnology |
| Market Cap | $1M | $781K |
| Revenue (TTM) | $109K | $600K |
| Net Income (TTM) | $-63M | $-33M |
| Gross Margin | -392.0% | 50.0% |
| Operating Margin | -116.1% | -58.2% |
| Total Debt | $9M | $34M |
| Cash & Equiv. | $209K | $41M |
BURU vs LYRA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BURU
LYRA
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| Nuburu, Inc. (BURU) | 100 | 0.1 | -99.9% |
| Lyra Therapeutics, … (LYRA) | 100 | 0.2 | -99.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BURU vs LYRA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LYRA leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Nuburu, Inc. is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
BURU
Nuburu, Inc.
The Long-Run Compounder
BURU is the clearest fit if your priority is long-term compounding.
- -99.9% 10Y total return vs LYRA's -100.0%
- -65.9% vs LYRA's -91.6%
Best for: long-term compounding
LYRA
Lyra Therapeutics, Inc.
The Income Pick
LYRA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.65
- Rev growth -1.5%, EPS growth -13.5%, 3Y rev CAGR 75.3%
- Lower volatility, beta 0.65, current ratio 3.41x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LYRA | -1.5% revenue growth vs BURU's -92.7% |
| Quality / Margins | LYRA | -54.9% margin vs BURU's -578.5% |
| Stability / Safety | LYRA | Beta 0.65 vs BURU's 1.21 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BURU | -65.9% vs LYRA's -91.6% |
| Efficiency (ROA) | LYRA | -60.2% ROA vs BURU's -479.1% |
BURU vs LYRA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLYRALAGGINGBURU
BURUNuburu, Inc.
0leads
LYRALyra Therapeutics, In…
3leads
6 Total Categories
CATEGORYLEADERvs BURUMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LYRA4/5
Valuation MetricsMultiples, price ratios, and targets
LYRA2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LYRA3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LYRA leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
LYRA is the larger business by revenue, generating $600,000 annually — 5.5x BURU's $108,912. LYRA is the more profitable business, keeping -54.9% of every revenue dollar as net income compared to BURU's -578.5%.
| Metric | BURUNuburu, Inc. | LYRALyra Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $108,912 | $600,000 |
| EBITDAEarnings before interest/tax | -$39M | -$34M |
| Net IncomeAfter-tax profit | -$63M | -$33M |
| Free Cash FlowCash after capex | -$8M | -$34M |
| Gross MarginGross profit ÷ Revenue | -3.9% | +50.0% |
| Operating MarginEBIT ÷ Revenue | -116.1% | -58.2% |
| Net MarginNet income ÷ Revenue | -578.5% | -54.9% |
| FCF MarginFCF ÷ Revenue | -69.8% | -56.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -87.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +82.1% | -17.8% |
LYRA leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
LYRA leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | BURUNuburu, Inc. | LYRALyra Therapeutics… |
|---|---|---|
| Market CapShares × price | $1M | $781,126 |
| Enterprise ValueMkt cap + debt − cash | $11M | -$5M |
| Trailing P/EPrice ÷ TTM EPS | -0.04x | -0.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.14x | 0.51x |
| Price / BookPrice ÷ Book value/share | — | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
LYRA leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
LYRA leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), LYRA scores 2/9 vs BURU's 1/9, reflecting mixed financial health.
| Metric | BURUNuburu, Inc. | LYRALyra Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | — | -10.3% |
| ROA (TTM)Return on assets | -4.8% | -60.2% |
| ROICReturn on invested capital | — | -145.5% |
| ROCEReturn on capital employed | — | -109.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | — | 2.97x |
| Net DebtTotal debt minus cash | $9M | -$6M |
| Cash & Equiv.Liquid assets | $209,337 | $41M |
| Total DebtShort + long-term debt | $9M | $34M |
| Interest CoverageEBIT ÷ Interest expense | -4.34x | — |
LYRA leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — BURU and LYRA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LYRA five years ago would be worth $10 today (with dividends reinvested), compared to $6 for BURU. Over the past 12 months, BURU leads with a -65.9% total return vs LYRA's -91.6%. The 3-year compound annual growth rate (CAGR) favors LYRA at -85.0% vs BURU's -89.2% — a key indicator of consistent wealth creation.
| Metric | BURUNuburu, Inc. | LYRALyra Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | -76.1% | -86.1% |
| 1-Year ReturnPast 12 months | -65.9% | -91.6% |
| 3-Year ReturnCumulative with dividends | -99.9% | -99.7% |
| 5-Year ReturnCumulative with dividends | -99.9% | -99.9% |
| 10-Year ReturnCumulative with dividends | -99.9% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -89.2% | -85.0% |
Evenly matched — BURU and LYRA each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BURU and LYRA each lead in 1 of 2 comparable metrics.
Risk & Volatility
LYRA is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than BURU's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BURU currently trades 5.6% from its 52-week high vs LYRA's 1.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BURUNuburu, Inc. | LYRALyra Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 0.65x |
| 52-Week HighHighest price in past year | $4.24 | $37.50 |
| 52-Week LowLowest price in past year | $0.15 | $0.44 |
| % of 52W HighCurrent price vs 52-week peak | +5.6% | +1.2% |
| RSI (14)Momentum oscillator 0–100 | 47.7 | 22.3 |
| Avg Volume (50D)Average daily shares traded | 41.8M | 159K |
Evenly matched — BURU and LYRA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BURUNuburu, Inc. | LYRALyra Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LYRA leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
Best OverallLyra Therapeutics, Inc. (LYRA)Leads 3 of 6 categories
Loading custom metrics...
BURU vs LYRA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BURU or LYRA a better buy right now?
For growth investors, Lyra Therapeutics, Inc.
(LYRA) is the stronger pick with -1. 5% revenue growth year-over-year, versus -92. 7% for Nuburu, Inc. (BURU). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BURU or LYRA?
Over the past 5 years, Lyra Therapeutics, Inc.
(LYRA) delivered a total return of -99. 9%, compared to -99. 9% for Nuburu, Inc. (BURU). Over 10 years, the gap is even starker: BURU returned -99. 9% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BURU or LYRA?
By beta (market sensitivity over 5 years), Lyra Therapeutics, Inc.
(LYRA) is the lower-risk stock at 0. 65β versus Nuburu, Inc. 's 1. 21β — meaning BURU is approximately 88% more volatile than LYRA relative to the S&P 500.
04Which is growing faster — BURU or LYRA?
By revenue growth (latest reported year), Lyra Therapeutics, Inc.
(LYRA) is pulling ahead at -1. 5% versus -92. 7% for Nuburu, Inc. (BURU). On earnings-per-share growth, the picture is similar: Nuburu, Inc. grew EPS 5. 6% year-over-year, compared to -13. 5% for Lyra Therapeutics, Inc.. Over a 3-year CAGR, LYRA leads at 75. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BURU or LYRA?
Lyra Therapeutics, Inc.
(LYRA) is the more profitable company, earning -60. 9% net margin versus -226. 9% for Nuburu, Inc. — meaning it keeps -60. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LYRA leads at -62. 8% versus -86. 4% for BURU. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BURU or LYRA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BURU or LYRA better for a retirement portfolio?
For long-horizon retirement investors, Lyra Therapeutics, Inc.
(LYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). Both have compounded well over 10 years (LYRA: -100. 0%, BURU: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BURU and LYRA?
These companies operate in different sectors (BURU (Industrials) and LYRA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(BURU: -92.7% · LYRA: -87.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.